title: Cell therapies and Parkinson's disease: where next? Interviewed by Emily Culme-Seymour.
abstract: Dr Roger A Barker is a University Reader in Clinical Neuroscience and Honorary Consultant in Neurology at the Addenbrooke's Hospital. He trained at Oxford and in London and has been in his current position for 10 years, having completed an MRC Clinician Scientist Fellowship prior to this. His main interests are in the neurodegenerative disorders of the nervous system, in particular Parkinson's disease and Huntington's disease. Dr Barker combines basic research investigating cell therapies to treat these conditions, with clinically based work on defining the natural history and heterogeneity of both diseases. He is a member of the CURE PD Research Advisory Panel and the MRC Stem Cell Liaison Committee. He is a member of the Regenerative Medicine editorial board and co-editor-in-chief of the journals ACNR and the Journal of Neurology.
authors.affiliation: Addenbrooke's Hospital, University of Cambridge, UK. rab46@cam.ac.uk.
authors.forename: Roger
authors.initials: R
authors.lastname: Barker
mesh_terms: D000818:Animals; D017690:Cell Transplantation; D004298:Dopamine / Q000627:therapeutic use; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy / Q000628:therapy*; D034421:Sus scrofa; D006113:United Kingdom
chemical_list: D004298:Dopamine